External validation of the discriminative validity of the ReSVinet score & development of simplified ReSVinet scores in secondary care

Author:

Sheikh Zakariya1ORCID,Potter Ellie1,Li You2ORCID,Drysdale Simon B3,Wildenbeest Joanne G4,Robinson Hannah5,McGinley Joseph5ORCID,Lin Gu-Lung5,Öner Deniz6,Aerssens Jeroen6,Justicia-Grande Antonio José7,Martinón-Torres Federico8,Pollard Andrew J5,Bont Louis4ORCID,Nair Harish9ORCID

Affiliation:

1. Edinburgh Medical School, College of Medicine and Veterinary Medicine, University of Edinburgh , Edinburgh , UK

2. School of Public Health, Nanjing Medical University , Nanjing , China

3. Centre for Neonatal & Paediatric Infection, St George’s, University of London , London , UK

4. Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children’s Hospital, University Medical Center Utrecht , Utrecht , The Netherlands

5. Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre , Oxford , United Kingdom

6. Infectious Diseases Translational Biomarkers, Janssen Pharmaceutica NV , Beerse , Belgium

7. Genetics, Vaccines and Infections Research Group (GENVIP). Instituto de Investigación Sanitaria de Santiago, University of Santiago , Santiago de Compostela , Spain

8. Department of Pediatrics, Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago de Compostela , Santiago de Compostela , Spain

9. Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh , Edinburgh , UK

Abstract

Abstract Background There is no consensus on how to best quantify disease severity in infants with respiratory syncytial virus (RSV) and/or bronchiolitis; this lack of a sufficiently validated score complicates the provision of clinical care and, the evaluation of trials of therapeutics and vaccines. The ReSVinet score appears to be one of the most promising; however it is too time-consuming to be incorporated into routine clinical care. We aimed to develop and externally validate simplified versions of this score. Methods Data were used from a multinational (Netherlands, Spain & United Kingdom) multicentre case-control observational study of infants with RSV to develop simplified versions of the ReSVinet by conducting a grid search to determine the best combination of equally weighted parameters to maximise for the discriminative ability of the scores across a range of outcomes (hospitalisation, intensive care unit admission, ventilation requirement). Subsequently discriminative validity of the score for a range of secondary care outcomes was externally validated by conducting a secondary analysis of data collected in infants with respiratory infection from tertiary hospitals in Rwanda and Colombia. Results Three candidate simplified scores were identified using the development dataset; they were excellent (area under the receiver-operator characteristic curve [AUROC] >0.9) in the development dataset at discriminating for a range of outcomes, and their performance was not statistically significantly different to the original ReSVinet score despite having fewer parameters. In the external validation datasets, the simplified scores were moderate-excellent (AUROC 0.7-1) across a range of outcomes. In all outcomes, except for in a single dataset at predicting admission to the high dependency unit, they performed at least as well as the original ReSVinet score. Conclusions Three promising candidate simplified scores were developed; however further external validation work in larger datasets, ideally from resource-limited settings needs to be conducted before any recommendation regarding their use.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3